Non-Viable Lactobacillus reuteri DSMZ 17648 (Pylopass™) as a New Approach to Helicobacter pylori Control in Humans

Association betweenHelicobacter pyloriand mortality in the NHANES III study

(2013) Yu Chen et al.   GUT

Management ofHelicobacter pyloriinfection—the Maastricht IV/ Florence Consensus Report

(2012) Peter Malfertheiner et al.   GUT

A Meta-Analysis of Probiotic Efficacy for Gastrointestinal Diseases

(2012) Marina L. Ritchie et al.   PLoS One

Evaluation of Helicobacter pylori eradication by triple therapy plus Lactobacillus acidophilus compared to triple therapy alone

(2011) J. A. Silva Medeiros et al.   EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES

Exploring Metabolic Pathway Reconstruction and Genome-Wide Expression Profiling in Lactobacillus reuteri to Define Functional Probiotic Features

(2011) Delphine M. Saulnier et al.   PLoS One

Diagnosis of Helicobacter pylori Infection

(2010) Xavier Calvet et al.   HELICOBACTER

Treatment of Helicobacter pylori Infection 2010

(2010) Anthony O’Connor et al.   HELICOBACTER

Epidemiology of Helicobacter pylori infection and Public Health Implications

(2010) Alexander C. Ford et al.   HELICOBACTER

The probiotic paradox: live and dead cells are biological response modifiers

(2010) Clifford A. Adams   NUTRITION RESEARCH REVIEWS

Inhibition of Helicobacter pylori Infection in Humans by Lactobacillus reuteri ATCC 55730 and Effect on Eradication Therapy: A Pilot Study

(2008) Ruggiero Francavilla et al.   HELICOBACTER